title: Clinical value of serum human epididymis protein 4 assay in the diagnosis of ovarian cancer: a meta-analysis.
abstract: OBJECTIVE
  Human epididymis protein 4 (HE4) has been approved for diagnosing ovarian cancer. The goal of this meta-analysis was to evaluate the clinical value of the serum HE4 in the diagnosis of ovarian cancer.
  
  
  METHODS
  The PubMed and Embase databases were searched to identify suitable studies. The sensitivity (SEN), specificity (SPE), and positive and negative likelihood ratios (PLR and NLR, respectively) of HE4 for the diagnosis of ovarian cancer were commonly used as bivariates. Summary receiver operating characteristic curves were used to summarize overall test performances. Meta-Disc 1.4 software was used to analyze the data.
  
  
  RESULTS
  A total of 6,269 patients from 31 trials were subjected to meta-analysis. The summary estimates of HE4 for ovarian cancer diagnosis were as follows: SEN 0.73 (95% confidence interval [CI] 0.71-0.75); SPE 0.89 (95% CI 0.88-0.90); PLR 7.30 (95% CI 5.42-9.84); and NLR 0.15 (95% CI 0.10-0.23). SEN 0.74 (95% CI 0.72-0.76); SPE 0.89 (95% CI 0.88-0.90); PLR 7.35 (95% CI 5.55-9.73); NLR 0.14 (95% CI 0.09-0.21).
  
  
  CONCLUSIONS
  Our study demonstrates that the sensitivity and specificity of HE4 was higher than that of cancer antigen 125. The results indicated that HE4 could be a useful tumor marker for ovarian cancer diagnosis. However, the results of this meta-analysis should be interpreted with caution, due to the heterogeneity among study designs. Further study should pay more attention to the possibility that HE4 can be a marker for monitoring recurrence of ovarian cancer.
authors.affiliation: Department of Gynecologic Oncology, Guangxi Medical University, Nanning, People's Republic of China.
authors.forename: Zhijun
authors.initials: Z
authors.lastname: Yang
authors.forename: Chunyin
authors.initials: C
authors.lastname: Wei
authors.forename: Zhaoqing
authors.initials: Z
authors.lastname: Luo
authors.forename: Li
authors.initials: L
authors.lastname: Li
keywords: CA125; HE4; meta-analysis; ovarian cancer
references.citation: Gynecol Oncol. 2013 Feb;128(2):233-8
references.pmid: 23200911
references.citation: Cancer Res. 2003 Jul 1;63(13):3695-700
references.pmid: 12839961
references.citation: Arch Gynecol Obstet. 2013 Jul;288(1):167-72
references.pmid: 23361457
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2496-506
references.pmid: 22028406
references.citation: Gynecol Oncol. 2008 Feb;108(2):402-8
references.pmid: 18061248
references.citation: Am J Obstet Gynecol. 2011 Oct;205(4):358.e1-6
references.pmid: 21722869
references.citation: Clin Chem. 2011 Nov;57(11):1534-44
references.pmid: 21933899
references.citation: Eur J Gynaecol Oncol. 1990;11(4):243-50
references.pmid: 2245807
references.citation: Clin Chem Lab Med. 2011 Mar;49(3):527-34
references.pmid: 21320028
references.citation: Gynecol Oncol. 2011 Jun 1;121(3):487-91
references.pmid: 21420727
references.citation: Zhonghua Fu Chan Ke Za Zhi. 2010 May;45(5):363-6
references.pmid: 20646446
references.citation: Int J Gynecol Cancer. 2012 Sep;22(7):1106-12
references.pmid: 22854652
references.citation: J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s
references.pmid: 12743135
references.citation: Zhonghua Fu Chan Ke Za Zhi. 2008 Dec;43(12):931-6
references.pmid: 19134334
references.citation: Diagn Pathol. 2013 Jan 23;8:11
references.pmid: 23343214
references.citation: Clin Chem Lab Med. 2011 Mar;49(3):521-5
references.pmid: 21288178
references.citation: BMC Cancer. 2012 Jun 19;12:258
references.pmid: 22712526
references.citation: Br J Cancer. 2009 Apr 21;100(8):1315-9
references.pmid: 19337252
references.citation: Int J Gynecol Cancer. 2012 Jul;22(6):1000-5
references.pmid: 22426406
references.citation: Gynecol Oncol. 2010 Mar;116(3):378-83
references.pmid: 19945742
references.citation: Int J Gynecol Cancer. 2011 Jul;21(5):852-8
references.pmid: 21633297
references.citation: Gynecol Oncol. 2012 Nov;127(2):379-83
references.pmid: 22835718
references.citation: Gynecol Oncol. 2008 Sep;110(3):374-82
references.pmid: 18584856
references.citation: Asian Pac J Cancer Prev. 2010;11(1):111-6
references.pmid: 20593939
references.citation: Int J Gynecol Cancer. 2012 Feb;22(2):238-44
references.pmid: 22214964
references.citation: Obstet Gynecol. 2011 Aug;118(2 Pt 1):280-288
references.pmid: 21775843
references.citation: Clin Chem Lab Med. 2012 Feb 03;50(8):1439-46
references.pmid: 22868811
references.citation: Br J Cancer. 2011 Mar 1;104(5):863-70
references.pmid: 21304524
references.citation: J Clin Lab Anal. 2009;23(5):331-5
references.pmid: 19774626